NAUT Quote, Financials, Valuation and Earnings

Genprex, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of --. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Genprex, Inc.'s return on equity of -900.4%.

Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 23.15%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 11060.71%. Given that Genprex, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Genprex, Inc. is more attractive than Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.771, suggesting its less volatile than the S&P 500 by 177.148%.

Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.

Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Genprex, Inc. quarterly revenues of --. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of 13.19%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 23.15%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Prelude Therapeutics, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -303.46%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.

Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 23.15%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 173.97%. Given that Prelude Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.

Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is higher than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 9.85x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pelthos Therapeutics, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -219.26%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Pelthos Therapeutics, Inc.'s return on equity of -241.95%.

Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 23.15%. On the other hand Pelthos Therapeutics, Inc. has an analysts' consensus of $59.80 which suggests that it could grow by 125.07%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..

Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pelthos Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pelthos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Pelthos Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Pelthos Therapeutics, Inc. quarterly revenues of $7.4M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is higher than Pelthos Therapeutics, Inc.'s net income of -$16.2M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Pelthos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 9.07x for Pelthos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.